Skip to content
  • 6,816 federal solicitations are open right now. How many of them are yours?
  • New solicitations are posted every day. The ones you never saw are the ones you cannot win.
  • Stop checking SAM.gov every morning. Let the contracts that fit your business come to you.
  • Tell Abierto what you sell in one sentence. AI reads every open solicitation for you.
  • Deadlines are short. Hear about a solicitation the day it is posted, not the week it closes.
  • Amendments move deadlines. Watch a solicitation and Abierto tells you when it changes.
  • See which contracts in your field are about to end, and who holds them today.
  • Plans from $39 a month. See your matches before you pay.
See plans
AbiertoGet started
Menu

Award notice, first published as solicitation

Advance the development of SCY-247, a novel antifungal currently in Phase 1 clinical trials, for the treatment of invasive candidiasis and prophylaxis of invasive fungal disease as oral and IC formula

BAA-23-100-SOL-00004

Office of Assistant Secretary for Preparedness and Response, Barda - Aspr / Daappo / Barda DCMA. Research and Development in Biotechnology (except Nanobiotechnology).

18 open like this View on SAM.gov Markdown

Awarded

Kaleo, Inc.

$33,258,615.00 obligated so far on USAspending

Get the next one like this from Office of Assistant Secretary for Preparedness and Response by email, the day it is posted.Find my opportunities

This one was awarded in 2028

18 like it are open now in research and development in biotechnology (except nanobiotechnology)

All 18 open in research and development in biotechnology (except nanobiotechnology)

Description

As published on SAM.gov with the solicitation of March 20, 2026.

We appreciate your interest in partnering with BARDA.

The latest BARDA Broad Agency Announcement (BAA) is Amendment 7 posted on March 19, 2026.

All contracting-related inquiries should be sent to BARDA-BAA@hhs.gov.

The final proposal submission deadline is September 25, 2028, at 4:30 PM Eastern Time for open areas of interest. 

Attachments

Files listed on SAM.gov. The ones we hold a copy of download from here; the rest open SAM's download, which needs no account.

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Kaleo, Inc.
UEI
LBM4GLJNDK31
CAGE
5LVP8
Vendor location
Richmond, VA
Contract
75A50124C00010, definitive contract
Obligated
$33,258,615.00, potential $33,762,976
Actions
4 between April 11, 2024 and March 16, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Development of a Novel Pralidoxime Chloride Auto-Injector Device
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Iqvia Government Solutions Inc.
UEI
T13YR5E14QY7
CAGE
1W4Y0
Vendor location
Falls Church, VA
Contract
75A50124C00029, definitive contract
Obligated
$3,322,007.00
Actions
2 between September 27, 2024 and November 10, 2025
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Contract Award to Further Develop the Beacon Model in a Series of Sequential Updates, Including Incorporating Recent Data Inputs, Augmenting the Outpatient Model Structure, And, If Data Permit, Developing Prediction Equations That Quantify the Combin
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Cerus Corporation
UEI
KJJQRRLY2FL5
CAGE
1PVJ6
Vendor location
Concord, CA
Contract
75A50124C00046, definitive contract
Obligated
$65,358,563.95, potential $209,038,158
Actions
4 between September 20, 2024 and July 21, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
License Pathogen Reduction Technology (Prt) for Red Blood Cell (Rbc) Components to Reduce the Risk of Transfusion-Transmitted Infection (Tti) by Recognized, Emerging, Epidemic, and Endemic Pathogens That Is Capable of Treating Over 10 Million RBC Com
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Synedgen, Inc.
UEI
HX79BD6YQ521
CAGE
5JGC8
Vendor location
Claremont, CA
Contract
75A50124C00047, definitive contract
Obligated
$18,828,663.00, potential $121,533,645
Actions
6 between September 26, 2024 and September 24, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Advance the Development of Paag17g (Drug Product: Miist305), a Once Daily, Orally Administered, Gut-Restricted Drug, to Reduce Mortality and Morbidity Arising from Acute Exposure to Ionizing Radiation, Specifically Gastrointestinal (Gi) Injury (Gi-Ar
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Gigagen Inc.
UEI
HF7MJJDVQQX5
CAGE
626U9
Vendor location
San Carlos, CA
Contract
75A50124C00049, definitive contract
Obligated
$29,618,612.89, potential $125,564,830
Actions
6 between September 25, 2024 and September 15, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Next Gen Recombinant Polyclonal Antibody Discovery Platform for the Develpment of Medical Countermeasures
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Lumos Diagnostics, Inc.
UEI
CRKMAE3F8ZJ1
CAGE
82T59
Vendor location
Carlsbad, CA
Contract
75A50124C00051, definitive contract
Obligated
$9,183,030.00
Actions
3 between September 26, 2024 and August 27, 2025
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Execution of the Clinical Method Comparison Study and Regulatory Submission Required to Be Granted Clia-Waiver from the FDA for Febridx Response to Baa-23-100-Sol-00004
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
4J Therapeutics Inc.
UEI
SZCGV7LQJKR4
CAGE
9DFF0
Vendor location
Palo Alto, CA
Contract
75A50124C00052, definitive contract
Obligated
$63,083,814.00, potential $362,232,711
Actions
6 between September 18, 2024 and September 18, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
The Overall Objective of This Contract Is to Demonstrate the Versatility and Efficacy of Our Programmable Antiviral Technology Platform by Assembling the Preclinical Package for LNA14, Performing a Phase 1A Study in Healthy Adult Human Subjects, and
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Sapphiros LLC
UEI
K9YCFNVM3E59
CAGE
9JCW2
Vendor location
Boston, MA
Contract
75A50125C00003, definitive contract
Obligated
$22,437,214.00, potential $26,931,926
Actions
2 between July 18, 2025 and September 14, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Low-Cost, Connected, Digital Lateral Flow Platform to Detect Influenza A, Influenza B, and Sars-Cov-2 for Use in Over-The-Counter (Otc) Settings
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Orexo US Inc.
UEI
MN1MPMBCVVD5
CAGE
6Y7L3
Vendor location
Morristown, NJ
Contract
75A50125C00010, definitive contract
Obligated
$11,450,712.00, potential $53,897,252
Actions
2 between September 24, 2025 and September 4, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Clinical Development of OX390 (Atipamezole) as an ?2 Agonist Reversal Agent for Human Use to Counteract the Sedative Effects of Xylazine, Medetomidine, and Other ?2 Agonists
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
University of California, Los Angeles
UEI
RN64EPNH8JC6
CAGE
4B557
Vendor location
Los Angeles, CA
Contract
75A50125C00011, definitive contract
Obligated
$9,188,827.00, potential $21,600,642
Actions
1 between September 29, 2025 and September 29, 2025
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Funding to the University of California Los Angeles to Support a Novel Pathogen Agnostic Diagnostic Platform Named the Swabseq Metagenomic Diagnostic Platform.
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Rafa Laboratories Ltd.
UEI
CKDNTKNDPMJ6
CAGE
0905A
Vendor location
Jerusalem
Contract
75A50125C00018, definitive contract
Obligated
$11,997,762.00, potential $147,733,954
Actions
2 between September 30, 2025 and August 10, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
The Scope of Work for This Contract Includes the Following Development Essentials: CMC Development, Pre-Clinical and Clinical Studies, Device Development Activities, Human Factors Testing, Market Viability Assessments Along with All Associated Regula
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Flosonics Medical LLC
UEI
RD81CL8M8EM9
CAGE
9UH24
Vendor location
Mountain View, CA
Contract
75A50126C00006, definitive contract
Obligated
$15,002,035.00, potential $69,809,569
Actions
1 between June 5, 2026 and June 5, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
The Purpose of This Contract Is to Advance the Development of Flopatch FP120 with Flopredict Alert for Burn and Blast Medical Countermeasure and Incorporates Eo 14398.
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Scynexis Inc.
UEI
H6PSJYEW3DT9
CAGE
33SU8
Vendor location
Jersey City, NJ
Contract
75A50126C00007, definitive contract
Obligated
$18,454,788.00, potential $213,943,726
Actions
1 between September 25, 2026 and September 25, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Advance the Development of SCY-247, a Novel Antifungal Currently in Phase 1 Clinical Trials, for the Treatment of Invasive Candidiasis and Prophylaxis of Invasive Fungal Disease as Oral and Ic Formula
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page
Recipient
Oxos Medical Inc.
UEI
D3KFHYMV6B17
CAGE
7P5Y3
Vendor location
Atlanta, GA
Contract
75A50126C00011, definitive contract
Obligated
$9,574,160.61, current value $24,445,826
Actions
1 between September 25, 2026 and September 25, 2026
Competition
Full and Open Competition, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Develop and Validate the Oxos X3, a Portable X-Ray System Designed to Transform Trauma Response by Bringing Hospital-Grade Imaging Directly to the Point of Need. This Effort Will Eliminate Critical Triage Bottlenecks During Mass Casualty Incidents WH
Match
solicitation number BAA23100SOL00004 equals the FPDS solicitation identifier; same awarding office 75A501 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. March 29, 2024

    Solicitation

    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

    Due September 25, 2028 at 4:30 PM EDT. SAM.gov, notice 764c53aa6dac43538ef902a2bc2af44f

    11 revisions on SAM
    • March 20, 2026: publish, solicitation
    • March 19, 2026: publish, solicitation
    • May 29, 2025: publish, solicitation
    • December 18, 2024: publish, solicitation
    • May 31, 2024: publish, solicitation
    • April 12, 2024: publish, award notice
    • April 23, 2024: publish, solicitation
    • March 29, 2024: publish, solicitation
    • December 22, 2023: publish, solicitation
    • November 9, 2023: publish, solicitation
    • September 26, 2023: publish, solicitation

  2. April 12, 2024

    Award notice, originally solicitation

    Development of a Novel Pralidoxime Chloride Auto-Injector Device (UNO-2-PAM)s

    Awarded to KALEO, Inc. Richmond for $27,139,602. SAM.gov, notice bdd0316393e449bdbddc8a3fd0d35f63

  3. April 23, 2024

    Solicitation

    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

    Due September 25, 2028 at 4:30 PM EDT. SAM.gov, notice 66a2877f5fb347b8988aba4ea1b07ecf

    10 revisions on SAM
    • March 20, 2026: publish, solicitation
    • March 19, 2026: publish, solicitation
    • May 29, 2025: publish, solicitation
    • December 18, 2024: publish, solicitation
    • May 31, 2024: publish, solicitation
    • April 23, 2024: publish, solicitation
    • March 29, 2024: publish, solicitation
    • December 22, 2023: publish, solicitation
    • November 9, 2023: publish, solicitation
    • September 26, 2023: publish, solicitation

  4. May 31, 2024

    Solicitation

    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

    Due September 25, 2028 at 4:30 PM EDT. SAM.gov, notice 8cdd54823bce4db5814e0b9a0fe63fac

    14 revisions on SAM
    • March 20, 2026: publish, solicitation
    • March 19, 2026: publish, solicitation
    • May 29, 2025: publish, solicitation
    • December 18, 2024: publish, solicitation
    • October 7, 2024: publish, award notice
    • September 26, 2024: publish, award notice
    • October 7, 2024: publish, award notice
    • September 21, 2024: publish, award notice
    • May 31, 2024: publish, solicitation
    • April 23, 2024: publish, solicitation
    • March 29, 2024: publish, solicitation
    • December 22, 2023: publish, solicitation
    • November 9, 2023: publish, solicitation
    • September 26, 2023: publish, solicitation

  5. September 26, 2024

    Award notice, originally solicitation

    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

    Awarded to LUMOS DIAGNOSTICS, Inc. Carlsbad for $8,258,774. SAM.gov, notice b1bbfc6cd6404ce5bd4e915a0a552c94

  6. December 18, 2024

    Solicitation

    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

    Due September 25, 2028 at 4:30 PM EDT. SAM.gov, notice 65e6d7784edd4eb083840c3794dc8d47

    10 revisions on SAM
    • March 20, 2026: publish, solicitation
    • March 19, 2026: publish, solicitation
    • May 29, 2025: publish, solicitation
    • December 18, 2024: publish, solicitation
    • May 31, 2024: publish, solicitation
    • April 23, 2024: publish, solicitation
    • March 29, 2024: publish, solicitation
    • December 22, 2023: publish, solicitation
    • November 9, 2023: publish, solicitation
    • September 26, 2023: publish, solicitation

  7. May 29, 2025

    Solicitation

    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

    Due September 25, 2028 at 4:30 PM EDT. SAM.gov, notice d832248e72e14c3c8cee96ee3c8b2170

    13 revisions on SAM
    • March 20, 2026: publish, solicitation
    • March 19, 2026: publish, solicitation
    • October 14, 2025: publish, award notice
    • October 14, 2025: publish, award notice
    • October 1, 2025: publish, award notice
    • May 29, 2025: publish, solicitation
    • December 18, 2024: publish, solicitation
    • May 31, 2024: publish, solicitation
    • April 23, 2024: publish, solicitation
    • March 29, 2024: publish, solicitation
    • December 22, 2023: publish, solicitation
    • November 9, 2023: publish, solicitation
    • September 26, 2023: publish, solicitation

  8. March 19, 2026

    Solicitation

    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

    Due September 25, 2028 at 4:30 PM EDT. SAM.gov, notice daeb33bc3f284cdd860073dbfe07e21c

    10 revisions on SAM
    • March 20, 2026: publish, solicitation
    • March 19, 2026: publish, solicitation
    • May 29, 2025: publish, solicitation
    • December 18, 2024: publish, solicitation
    • May 31, 2024: publish, solicitation
    • April 23, 2024: publish, solicitation
    • March 29, 2024: publish, solicitation
    • December 22, 2023: publish, solicitation
    • November 9, 2023: publish, solicitation
    • September 26, 2023: publish, solicitation

  9. March 20, 2026

    Solicitation

    Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)

    Due September 25, 2028 at 4:30 PM EDT. SAM.gov, notice 8170c4735df64714adb2d1f8ce8671b1

    11 revisions on SAM
    • June 5, 2026: publish, award notice
    • March 20, 2026: publish, solicitation
    • March 19, 2026: publish, solicitation
    • May 29, 2025: publish, solicitation
    • December 18, 2024: publish, solicitation
    • May 31, 2024: publish, solicitation
    • April 23, 2024: publish, solicitation
    • March 29, 2024: publish, solicitation
    • December 22, 2023: publish, solicitation
    • November 9, 2023: publish, solicitation
    • September 26, 2023: publish, solicitation

  10. September 25, 2026

    Award notice

    Awarded to Scynexis, Inc. Jersey City for $213,943,726. SAM.gov, notice 5d2b1c5f6d094d72ad9916f20fc33ed3

    1 revisions on SAM
    • September 25, 2026: publish, award notice

Points of contact